Why PreciseDx

Seeing more in what’s already visible

We’ve long known that the secrets of cancer can be seen directly in their cellular structure, but in the past we could only look at that structure qualitatively. PreciseDx changes that.

PreciseBreast™ uses OncoIntelligence™ , our proprietary AI-platform, to combine 7 morphologic features with 4 clinical factors to produce a single OncoIntelligence Score™ between 0 and 100.
‍
PreciseBreast™, clinically validated in more than 3,000 breast cancer cases^1,2,3, accurately and reliably stratifies patients into two cohorts based on risk of disease recurrence at 6 years.

Low risk patients have, on average, a 6% recurrence risk, while high risk patients have, on average, a recurrence risk of 24%.

1) Gerardo Fernandez et al, 2022. Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years. Breast Cancer Research, 24(1), pp.1-11.

2) Physicians from MCI ordered the 21-gene assay for prospective clinical treatment decisions 6 years ago. This cohort represents the same patients’ stored H&E-stained glass slides that were then tested with PreciseBreast to report predicted prognostic outcomes. As reported at SABCS 2024, outcome data has been kept for these patients to match with test scores.
‍
3) Specimen was collected from the Laboratory of Pathology, Dordrecht Albert Schweitzer Hospital, the Netherlands on patients that were prospectively tested with the 70-gene assay for prospective clinical treatment decisions 6 years ago. This cohort represents the same patients’ stored H&E-stained glass slides that were then tested with PreciseBreast to report predicted prognostic outcomes. As reported at ESMO 2024, outcome data has been kept for these patients to match with test scores.